QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.058149v1 308/3/857    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Simpson, L. L. Articles by Bora, R. S. Search for Related Content PubMed PubMed Citation Articles by Simpson, L. L. Articles by Bora, R. S.

TOXICOLOGY

The Role of the Interchain Disulfide Bond in Governing the Pharmacological Actions of Botulinum Toxin

Department of Medicine (L.L.S., A.B.M., J.-B.P., R.S.B.) and Department of Biochemistry and Molecular Pharmacology (L.L.S.), Jefferson Medical College, Philadelphia, Pennsylvania

All serotypes of botulinum toxin possess a disulfide bond that links the heavy chain and light chain components of the holotoxin. Experiments were done to assess the functional significance of this covalent bond, and the work was facilitated by use of mercurial compounds that modify residues in the vicinity of the catalytic site. The data indicated that reduction of the interchain disulfide bond had two major effects: 1) changing conformation or orientation of the two chains, which diminished toxicity against intact cells, and 2) loosening or relocating a heavy chain belt segment that encircles the light chain and occludes the catalytic site. Interestingly, disulfide bond reduction of all serotypes produced conformational changes that diminished toxicity against intact cells, but it produced conformational changes that led to exposure of the catalytic site in only three serotypes. For the other serotypes, the catalytic site was accessible even before disulfide bond reduction. Neither of the major structural effects was dependent upon separation of the heavy chain and light chain components of the toxin, nor were they dependent on toxin substrate. Depending on the initial state of the toxin molecule, the combination of disulfide bond reduction and treatment with a mercurial compound could abolish toxicity. Therefore, this combination of treatments was used to convert active toxin into a parenteral vaccine. Administration of the modified toxin evoked a substantial IgG response, and it produced complete protection against a large dose of native toxin.

Address correspondence to: Dr. Lance L. Simpson, Professor of Medicine, Jefferson Medical College, 1020 Locust Street, Room 314-JAH, Philadelphia, PA 19107. E-mail: lance.simpson{at}jefferson.edu

This article has been cited by other articles:

				F. H. Al-Saleem, D. M. Ancharski, E. Ravichandran, S. G. Joshi, A. K. Singh, Y. Gong, and L. L. Simpson The Role of Systemic Handling in the Pathophysiologic Actions of Botulinum Toxin J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 856 - 863. [Abstract] [Full Text] [PDF]

				E. Ravichandran, Y. Gong, F. H. A. Saleem, D. M. Ancharski, S. G. Joshi, and L. L. Simpson An Initial Assessment of the Systemic Pharmacokinetics of Botulinum Toxin J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1343 - 1351. [Abstract] [Full Text] [PDF]